Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00361101 · ClinicalTrials.gov registry record · Phase 1

A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus

A Phase 1 study of HIV Infections and X4 Tropic Virus, sponsored by Genzyme, a Sanofi Company.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
2
Study locations

NCT00361101: Completed Phase 1 study of HIV Infections and X4 Tropic Virus, sponsored by Genzyme, a Sanofi Company.

NCT00361101 is a Phase 1 study of HIV Infections and X4 Tropic Virus that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 10 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00361101, a Phase 1 study of HIV Infections and X4 Tropic Virus, has completed, sponsored by Genzyme, a Sanofi Company.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the safety and activity of AMD11070 in HIV-infected patients carrying X4-tropic virus.

Interventions

  • DRUG AMD11070

Study Locations (2)

Florida

  • - Orlando

Other

  • - London

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2005-10
Est. Completion 2010-04
Phase Phase 1
Genzyme, a Sanofi Company

196 total trials

What the finished NCT00361101 record still lists

NCT00361101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which AMD11070 is the first listed.

NCT00361101 reports a single indexed study location in Florida, Other.

Frequently Asked Questions

What is clinical trial NCT00361101 about?

NCT00361101 is a clinical study titled "A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus". The purpose of this study is to determine the safety and activity of AMD11070 in HIV-infected patients carrying X4-tropic virus.

What is the current status of trial NCT00361101?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2005-10. Estimated completion is 2010-04.

What conditions does trial NCT00361101 study?

This clinical trial studies the following conditions: HIV Infections, X4 Tropic Virus.

What interventions are being tested in trial NCT00361101?

The interventions under investigation include: AMD11070 (DRUG).

Who is sponsoring clinical trial NCT00361101?

This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00361101 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00361101's enrollment target sits among peer trials

10 526th of 542 higher than 14 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00361101, the US trial registry maintained by the National Library of Medicine. NCT00361101 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.